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Antiviral activity of silymarin 
against chikungunya virus
Rafidah Lani1, Pouya Hassandarvish1, Chun Wei Chiam1, Ehsan Moghaddam1, 
Justin Jang Hann Chu2, Kai Rausalu3, Andres Merits3, Stephen Higgs4, 
Dana Vanlandingham5, Sazaly Abu Bakar1 & Keivan Zandi1
The mosquito-borne chikungunya virus (CHIKV) causes chikungunya fever, with clinical presentations 
such as severe back and small joint pain, and debilitating arthritis associated with crippling pains 
that persist for weeks and even years. Although there are several studies to evaluate the efficacy 
of drugs against CHIKV, the treatment for chikungunya fever is mainly symptom-based and no 
effective licensed vaccine or antiviral are available. Here, we investigated the antiviral activity of 
three types of flavonoids against CHIKV in vitro replication. Three compounds: silymarin, quercetin 
and kaempferol were evaluated for their in vitro antiviral activities against CHIKV using a CHIKV 
replicon cell line and clinical isolate of CHIKV of Central/East African genotype. A cytopathic effect 
inhibition assay was used to determine their activities on CHIKV viral replication and quantitative 
reverse transcription PCR was used to calculate virus yield. Antiviral activity of effective compound 
was further investigated by evaluation of CHIKV protein expression using western blotting for CHIKV 
nsP1, nsP3, and E2E1 proteins. Briefly, silymarin exhibited significant antiviral activity against CHIKV, 
reducing both CHIKV replication efficiency and down-regulating production of viral proteins involved 
in replication. This study may have important consequence for broaden the chance of getting the 
effective antiviral for CHIKV infection.
Malaysia encompasses tropical rainforests and swamps, which are the niche for several mosquito-borne 
viruses. However, due to massive urbanization and deforestation several of these viruses were easily 
introduced to our human population including chikungunya virus (CHIKV). CHIKV is a member of 
Togaviridae family (genus Alphavirus) and causes chikungunya fever in humans. It was first isolated 
from the dengue-like outbreak in Tanzania (East Africa)1–3. Apart from the usual clinical manifestations 
such as fever, headache, lymphadenitis and rashes, the most prominent complaint from infected person 
is the chronic pain and stiffness due to arthritis or swelling of small joints which remains for weeks or 
even years, as define in the Makonde language in which ‘Chikungunya’ means ‘that which bends up,4–6.
Recently CHIKV infections emerged in Kenya and then were recorded in Comoros during 2004 with 
5000 cases being reported. La’ Reunion in France (2005–2006), together with neighboring islands in 
the Indian Ocean, Seychelles, Madagascar, Mauritius and Mayotte; experienced an explosive outbreak 
with 300,000 cases and 237 deaths. CHIKV subsequently spread to India and Southeast Asia causing 
large-scale epidemics. In 2008, CHIKV was categorized as a Category C priority pathogen in the list of 
US National Institute of Allergy and Infectious Diseases (NIAID). To this date, more than 50 countries 
have been identified to be at risk2,7.
1Tropical Infectious Disease Research and Education Center (TIDREC), Department of Medical Microbiology, 
Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia. 2Laboratory of Molecular RNA Virology and 
Antiviral Strategies, Department of Microbiology, Yong Loo Lin School of Medicine, National University of 
Singapore, Singapore. 3Institute of Technology, University of Tartu, Tartu, Estonia. 4Biosecurity Research Institute, 
Kansas State University, Manhattan, USA. 5Department of Diagnostic Medicine and Pathobiology, Kansas State 
University, Manhattan, USA. Correspondence and requests for materials should be addressed to K.Z. (email: 
keivan@um.edu.my)
Received: 15 January 2015
Accepted: 26 May 2015
Published: 16 June 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:11421 | DOi: 10.1038/srep11421
Phylogenetic analysis shows that CHIKV has three genotype variants; West African, East/Central/
South African (ECSA) and Asian8. Malaysia had its first outbreak in late 1998 at the suburb Klang in the 
state of Selangor and the CHIKV was identified as Asian genotype. Localized outbreaks and clustered 
cases were reported in Larut Matang, Lama, Perak. The ECSA genotype virus caused outbreaks after 
2006. In early 2008, together with the neighboring Singapore, the epidemic in Johor began. This spread 
throughout states in Peninsular Malaysia and in 2009, many cases occurred in Selangor, Melaka, Negeri 
Sembilan and Pahang states and peaked in Kelantan, Kedah, Terengganu, Perlis and Sarawak4,9,10. From 
April 2008 until March 2010, over 10,000 cases were reported in these nationwide outbreaks, although 
there were no fatalities11.
The main mosquito vectors for CHIKV are A. aegypti and A. albopictus3,4,7. A. aegypti was a pri-
mary vector for the outbreak that happened in Kenya, Comoros, Africa and Asia, but the ‘Asian Tiger 
Mosquitoe’ A. albopictus was the main vector for the Reunion and subsequent Indian Ocean outbreak12. 
Vector switching to A. albopictus became predominant due to the substitution of Alanine residue 226 to 
Valine residue in the CHIKV E1 protein (A226V)13. This convergent mutation seems to be due to the 
selective pressure as the impact of different and new environment or ecosystem.
Extensive studies continue around the world to find an effective cure, safe antiviral treatment or 
vaccine for CHIKV infection. In one study it was shown that chloroquine phosphate, an antimalar-
ial drug, can decrease the intensity or duration of pain, and number of joints involved. However, the 
effectiveness of chloroquine to treat chronic symptoms could not be evaluated due to the lack of ade-
quate control patients with these symptoms14. The synergistic effect of ribavirin with interferon alpha 2B 
against CHIKV infection was reported only in an in vitro study6. It has been shown that arbidol strongly 
interferes with the early stages of CHIKV infection by targeting the cellular membrane. However, it is 
only a potent inhibitor against in vitro CHIKV infection15.
Flavonoids are polyphenolic compounds that are present in different plants, foods and drinks. 
Flavonoids are well known for their different biological properties including: antimicrobial activity, 
anti-inflammatory activity, anti-allergic activity, and cytotoxic antitumor activity16. Quercetin has anti-
viral activity against herpes simplex virus (HSV) type-1, respiratory syncytial virus, pseudorabies virus, 
parainfluenza virus type 3 and Sindbis virus, a type member of genus Alphavirus. The mechanism of 
actions of quercetin includes: enhancing the antiviral activity of interferon, binding to viral proteins, 
and interfering with viral nucleic acid synthesis by binding to the viral polymerases. Another flavonoid, 
kaempferol is active against HSV, human coronavirus and rotavirus replication17.
Silymarin, extracted from milk thistle (Silybum marianum), was shown to inhibit hepatitis C virus 
(HCV) in both in vitro and in vivo by inhibiting HCV entry, RNA synthesis, viral protein expression 
and infectious virus production; in addition it also acts by blocking of the virus cell-to-cell spread18. It 
becomes our concern to explain the definition for the nomenclature of ‘milk thistle extract’, ‘silymarin’ 
and ‘silibinin’ since the findings that will be discussed further involve these three important terms. In 
brief, the initial extract of the crushed milk thistle seeds made up of 65–80% silymarin and 20–35% 
fatty acids, such as linoleic acid. Silymarin itself, is a complex of more than 7 flavonolignans (silybin A, 
silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin and silydianin) and 1 flavonoid whereas 
silibinin is a semi-purified, commercially available fraction of silymarin, with an approximate 1:1 mixture 
of 2 diastereoisomeric compounds, silybin A and silybin B which are also referred to in the literature as 
silibinin A and B19.
Here we evaluated in vitro antiviral activity of quercetin, kaempferol and silymarin against a clinical 
isolate of CHIKV. Our results support the antiviral properties of silymarin as a promising compound for 
further investigations towards the development of an anti-CHIKV drug.
Results
Cytotoxicity of flavonoids. The MTS assay was used to determine cytotoxicity of each flavonoid for 
Vero and BHK cells. The CC50 value of each compound was calculated (Table 1). There was no observed 
Compounds Vero cells BHK-21 cells
CC50 
(μg/ml)
MNTD 
(μg/ml)
CC50 
(μg/ml)
MNTD 
(μg/ml)
Silymarin 425.1 > 200 305.4 > 150
Quercetin > 1000 > 400 1665 > 500
Kaempferol > 1000 > 400 537.3 > 200
Silybin > 200 > 50 NA* NA*
Table 1.  Cytotoxicity of flavonoids against Vero cells and BHK-21 cells. *NA: not applicable. MTS 
assay was used to evaluate the cytotoxicity of the compounds. Different concentrations of tested flavonoids 
up to 800 μ g/ml were used to treat the Vero cells and BHK-21 cells for 2 days. The maximum non-toxic 
dose (MNTD) of silymarin as the effective compound against CHIKV is > 200 μ g/ml (on Vero cells) and 
> 150 μ g/ml (on BHK21 cells) as more than 95% of the treated cells are viable.
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cytotoxicity for cells treated with 0.1% DMSO (final concentration of solvent, used to dissolve flavonoids, 
in cell culture media).
Antiviral activity assay. Primary screening. Different non-cytotoxic concentrations of silymarin, 
kaempferol and quercetin were tested on CHIKV-infected Vero cells to find the effective compound. A 
CPE inhibition assay was used at 48 hpi. It was shown that 100 μ g/ml of silymarin significantly inhibited 
the CHIKV-CPE presentation (P = 0.0007) (Fig.  1a). This finding was not unexpected as silybin (also 
known as silibinin) is one of the components of silymarin and has been shown to possess anti-CHIKV 
activity20. In contrast, the highest concentrations of quercetin and kaempferol only exhibited 25% CPE 
inhibitory activity (Fig. 1a). The results of CPE inhibition assay were further confirmed by using MTS 
assay (Fig. 1b).
Silymarin  inhibits  early  post-entry  stages  of  CHIKV  replication.  From analyzed compounds 
only silymarin was able to suppress CHIKV mediated cytotoxicity. Therefore it was chosen for a 
time-of-addition assay performed with aim to determine which stage of virus infection cycle this com-
pound affected.
As it is shown in Fig.  2 the inhibition was most efficient when silymarin was added at 2  hpi. The 
time-dependence of inhibitory effect of compound is coherent with hypothesis that its anti-CHIKV 
activity may be due inhibition of some early, but probably post-entry, step of CHIKV replication cycle. 
Figure 1. Silymarin inhibits CHIKV induced cytotoxic effects. CPE inhibition (a) and cell viability 
analysis by MTS assay (b) was carried out using Vero cells infected at an MOI = 1. Cells were treated with 
increasing concentrations (both kaempferol and quercetin concentration tested as high as 200 μ g/ml) of 
indicated flavonoids and assayed 48 h post treatment. Results of panel (a) are normalized to respective values 
obtained for non-infected control cells which were set as 100% for each compound. CPE inhibition assay 
result shows that silymarin exhibits statistically significant (P < 0.05) dose-dependent inhibition on CPE 
presentation. Data from triplicate assays were plotted and analyzed from a Pearson two-tailed test (Graph 
Pad Prism Version 5, Graph Pad Software Inc., San Diego, CA).
Figure 2. Silymarin inhibits early post entry stages of CHIKV replication cycle. The Vero cells were 
treated with 100 μ g/ml of silymarin at stated time-points and infected with CHIKV at an MOI = 1 (“0” 
time point). Copy number of viral RNA in supernatants at was measured at 48 h pi. Using qRT-PCR. Data 
from triplicate assays were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, 
CA). Error bars represent standard deviation. VC- vehicle control (cells treated with media containing 0.1% 
DMSO only).
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Anti-entry assay has also been performed and the result has clearly shown that there is no antiviral 
activity of silymarin against CHIKV at the anti-entry phase (Fig. 3).
Evaluation of antiviral effect of silymarin using CHIKV replicon cell line.  The CHIKV replicon 
cell line contained non-cytotoxic replicon of CHIKV which, in addition to the virus replicase proteins, 
expresses also puromycin acetyl transferase, EGFP and Rluc markers20. In this system the Rluc activity is 
proportional to viral replicon RNA replication. It was found that 100 μ g/ml of silymarin suppressed the 
activity of Rluc marker expressed by the CHIKV replicon by 93.4% (Fig. 4). The inhibition was highly 
significant (P = 0.016) confirming that silymarin affects post-entry steps of CHIKV infection. This data 
also indicates that silymarin can interfere with CHIKV RNA replication by affecting the viral replicase 
system. Interestingly, in previous study20 IC50 of silybin, one of the major components of silymarin, was 
estimated as 59.8 μ M (approximately 30 μ g/ml). Compared to this silymarin was somewhat more efficient 
as nearly three-fold inhibition was observed at 25 μ g/ml indicating that other components of silymarin 
likely contributed to its anti-CHIKV activity.
Silymarin  interferes  with  post-entry  stages  of  CHIKV  infection  in  a  dose  dependent man-
ner.  To confirm the post-entry antiviral activity of silymarin against CHIKV a virus yield assay using 
qRT-PCR was used. The CHIKV RNA copy number in supernatants of cells treated with each concentra-
tion of inhibitor and that from the control cells was interpreted and depicted (Fig. 5). There is a signifi-
cant reduction of CHIKV replication as treated with increasing concentrations of silymarin (P = 0.0199), 
Figure 3. Effect of silymarin against CHIKV cell entry. Silymarin does not exhibit statistically significant 
(P > 0.05) dose-dependent inhibition against CHIKV internalization to the Vero cells. Vehicle–treated 
(0.1% DMSO) cells were used as control (“0”) concentration). Data from triplicate assays were plotted and 
analyzed from a non-parametric correlation (Spearman) two-tailed test (Graph Pad Prism Version 5, Graph 
Pad Software Inc., San Diego, CA).
Figure 4. Evaluation of anti-CHIKV activity of silymarin using BHK-CHIKV-NCT replicon cell line. 
Silymarin exhibits a statistically significant (P < 0.05) dose-dependent inhibition on the Rluc activity 
produced by BHK-CHIKV-NCT replicon. The Rluc activity was measured at 48 h post treatment. Vehicle–
treated (0.1% DMSO) cells were used as control (“0”) concentration). Data from triplicate assays were 
plotted and analyzed from a non-parametric correlation (Spearman) two-tailed test (Graph Pad Prism 
Version 5, Graph Pad Software Inc., San Diego, CA).
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as compared to the vehicle control treated cells. Based on this data it was calculated that silymarin 
had IC50 =  16.9 μ g/ml with Selectivity Index (SI) of 25.1. Taking into account that adding silymarin 
2 hpi showed significant inhibitory effect against CHIKV replication confirms that silymarin acts at the 
post-entry stage of CHIKV infection. In contrast, in similar assay neither kaempferol nor quercetin 
showed any significant inhibitory effect against CHIKV replication (Fig.  5). As it is shown in Fig.  5, 
100 μ g/ml of silymarin can inhibit the CHIKV yield by more than 99%.
To evaluate whether the silymarin also affects the CHIKV protein synthesis, a series of western blot 
analyses were performed using lysates of the CHIKV infected and silymarin treated Vero cells (Fig. 6). 
As it is evident from constant levels of β actin, silymarin treatment did not result in protein degradation 
and, at used concentrations, the compound was not toxic for the Vero cells. In contrast, dose-dependent 
reduction of amounts of nsP1, nsP3 and E2 proteins was observed (Fig.  6) indicating that silymarin 
limited CHIKV replication and virus-encoded protein synthesis within the treated cells.
Silybin  interferes  with  early  post-entry  of  CHIKV  infection  in  dose-dependent  man-
ner.  Questioned by whether the silymarin effects on the CHIKV replication are influenced by the 
fractions it is made up of, since the study done by Pohjala L. et al., 2011 has proved that the silybin (one 
of the silymarin fraction) can suppressed the activities of Rluc marker gene expressed by the CHIKV 
replicon, we have evaluated the effect of silybin against CHIKV intracellular replication. Hence, silybin 
was tested for its early post-entry activity and we confirmed its anti-CHIKV activity in a dose-dependent 
manner with the IC50 of 69.7 µg/ml, which is higher than the IC50 of silymarin. This result makes us 
to conclude that the activity of silymarin against CHIKV replication might also be enhanced by other 
components or fractions that made it up.
Discussion
Considering the crippling pains that persist for weeks and even years due to CHIKV infections and the 
absence of antiviral treatment for the virus, the search for effective antiviral compounds is imperative. 
Figure 5. Silymarin reduces CHIKV RNA copy number in growth medium in dose dependent manner. 
Silymarin exhibits a statistically significant (P < 0.05) dose-dependent inhibition of CHIKV RNA levels. 
As it is shown in the figure, there is no significant inhibitory effect from quercetin and kaempferol against 
CHIKV intracellular replication (P > 0.05). Statistical significance is analyzed from a Pearson two-tailed test 
(Graph Pad Prism Version 5, Graph Pad Software Inc., San Diego, CA).
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Due to their known broad spectrum anti-viral activity and low toxicity, we evaluated three flavonoids 
as viable candidate compounds21. From these compounds only silymarin was identified as the flavonoid 
with significant anti-CHIKV activity. It was considered that it has potential for future development as its 
use results in ≥ 70% reduction of CHIKV infection based on CPE inhibition and MTS assays (Fig. 1). 
Remarkably, the effective concentration of silymarin was much lower than MNTD. In contrast, neither 
kaempferol nor quercetin showed significant antiviral activity against in vitro replication of CHIKV in 
both assays.
To quantify the copy number of viral RNA released (most probably in form of genomic RNA packed 
into virions) from infected cells were used qRT-PCR and amplified part of nsP3 encoding region of 
CHIKV genome. Since nsP3 which is involved in the negative-strand and subgenomic RNA synthesis, 
the quantification of the negative-strand RNA reflects the active viral replication, we selected the nsP3 
as the gene target for qRT-PCR to quantify the virus load during replication22–25. Our data demonstrated 
that treatment with silymarin results in effective reduction of number of released viral genome indicating 
reduction of viral RNA synthesis and/or virion formation and release.
In post-adsorption assay silymarin taken at 100 μ g/ml resulted in ≈ 99% inhibition of CHIKV repli-
cation. We therefore performed a time-of-addition assay using this concentration of silymarin to deter-
mine the stage of infection where the silymarin treatment results in biggest antiviral effect. The result 
was consistent with our data from post-adsorption assay; hence it can be concluded that silymarin is 
most effective if it is added shortly after virus infection (2 hpi). The reason for lower anti-CHIKV activ-
ity of pretreatment with silymarin could be due to the half-life of silymarin which based on previous 
Figure 6. Silymarin suppresses accumulation of CHIKV-encoded proteins. Western blot analysis was 
performed to determine the effect of silymarin on production of CHIKV nsP1, nsP3 and E2 proteins. (a) 
Bands of the specific proteins as observed on the blot. A dose dependent reduction of CHIKV nsP1, nsP3 
and E2 proteins were observed upon silymarin treatments for 48 h. (b) The above mentioned observation 
confirmed by calculating the relative band intensity (calculated from the band intensity of sample/band 
intensity of β -actin loading control) using Image J. β -actin is used as a loading control for each set of 
samples.
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bioavailability study is less than 4 hours26, although, there is no data available on in vitro half-life or 
stability of silymarin which might be interesting for future studies.
As our findings were consistent with hypothesis that silymarin effect on post-entry stages of CHIKV 
dose response analysis was also performed using a CHIKV replicon cell line where no virus entry or exit 
takes place. Again, it was found that silymarin is able to suppress the activity of Rluc marker expressed 
by CHIKV replicon. This finding is consistent with that from previous assay and confirms that silymarin 
suppresses CHIKV RNA replication and does it in dose-dependent manner. The Rluc, expressed by 
CHIKV replicon, is fused to nsP3 protein of the virus. Accordingly, reduction of Rluc activity indicates 
reduced amounts of nsP3-Rluc protein in CHIKV replicon cell line.
To further confirmation of anti-CHIKV activity of silymarin, we have shown the effect of silymarin 
on viral protein synthesis in CHIKV infected cells (Fig.  5). Again decrease of viral protein synthesis 
was observed. This effect could be due to inhibition of CHIKV RNA replication and/or transcription. 
However, as in virus expression and replicon cell lines the synthesis of viral RNAs and proteins are 
coupled further study is necessary to evaluate the direct effect of silymarin on inhibition of newly syn-
thesized CHIKV proteins. It is possible that some of non-structural proteins of CHIKV represents direct 
target for silymarin. The possibilities include nsP1 protein, which is involved in the synthesis of the 
negative strand of viral RNA and RNA capping, and nsP3 protein, that is another component of the 
viral replicase complex. Down regulation of E2 expression may represent consequence of suppression of 
replication (directly or via inhibition of ns-protein(s)). However, this down regulation is clearly relevant 
from point of view of development of effective antiviral as E2 protein is one of the important virion gly-
coproteins and is essential for receptor binding. Interestingly, a previous study showed that silymarin can 
inhibit the expression of NS5B of hepatitis C virus (HCV) which is catalytic subunit of HCV replicase26. 
Although, the hepatoprotective property of silymarin in the context of blocking HCV infection based 
on in vivo studies is another important criteria for this compound to be considered as a therapeutic 
candidate for hepatitis C19,27,28.
This study represents an important first report on the anti-CHIKV properties of silymarin. Previously 
other flavonoids such as apigenin, chrysin, naringenin and silybin, which are also one of components 
of silymarin, are known to be inhibitors of viral replication mainly through affecting important cellular 
elements for CHIKV replication20. However, inhibitory properties of silymarin are somewhat different 
from that of silybin. Thus our data for silymarin warrants further mechanistic studies to characterize 
the antiviral properties of all its components and other flavonoid compounds and head-to-head com-
parison of their antiviral effects at lower concentrations/ different conditions so that the best option of 
anti-CHIKV can be determined.
Conclusion
In summary, our study showed that silymarin exhibited significant in vitro antiviral activity against 
CHIKV. It suppressed post-entry stages of viral replication, most likely CHIKV RNA replication sig-
nificantly with a dose dependent manner. Coherent with this the expression of proteins, needed for 
RNA replication, and also expression of viral structural E2 protein were down-regulated. In contrast to 
silymarin it was found that quercetin and kaempferol are unable to suppress CHIKV replication and 
accordingly are not good candidates for anti-CHIKV drugs. These findings warrant future mechanistic, 
in vivo anti-viral, toxicity and pharmacokinetic studies as part of the process for evaluation of silymarin 
as a potential anti-CHIKV therapeutic.
Materials and Methods
Virus and cells. The CHIKV isolate used in this experiment was a clinical isolate from an outbreak 
in Johor in 2008 coded as MY/065/08/FN295485. It belongs to the ECSA genotype and has the A226V 
mutation in E1 protein29,30. BHK-21 (baby hamster kidney) and Vero (African green monkey kidney) 
cells from the American Type Culture Collection (ATCC) were used in this study. Vero cells have been 
widely used in the in vitro antiviral research for example in the antiviral testing for the chikungunya 
virus, human enterovirus 71 and Coxsackievirus A1631,32. Both cell lines were cultured using Eagle’s 
Minimum Essential Medium (EMEM, Gibco, NY, USA) containing 10% inactivated fetal bovine serum 
(FBS) and penicillin-streptomycin, and incubated at 37°C with 5% CO2.
The CHIKV MY/065/08/FN295485 strain was propagated in BHK-21 cells and harvested after full 
cytopathic effect (CPE) was observed. Virus stock titer was determined by the tissue culture infectious 
dose 50 (TCID50) methods33; then the obtained stock was aliquoted and stored at –70 °C. During the 
time of virus propagation and antiviral assay the FBS concentration of the cell culture medium was 
reduced to 2%. Vero cell line was used for further experiments such as MTS assay and antiviral assays.
The CHIKV replicon cells20 were grown and maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Gibco, NY, USA) supplemented with 8% fetal bovine serum (FBS), 2% tryptose-broth phos-
phate and penicillin-streptomycin, and incubated at 37°C with 5% CO2.
Flavonoids.  Silymarin, quercetin and kaempferol were purchased from Sigma-Aldrich Corporation 
(Sigma-Aldrich, St. Louis, MO, USA). Silybin was purchased from Selleckchem Corporation (Selleckchem, 
TX, USA). The stock solutions of flavonoids, 50 μ g/ml, were prepared in dimethyl sulfoxide (DMSO) 
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(Sigma-Aldrich, St. Louis, MO, USA) and stored in − 20 °C for future use. Stock solution was diluted 
with EMEM and was filtered through a syringe filter with 0.2 μ m pore size (Millipore, MA, USA) at the 
time of use; DMSO concentration in working solutions prepared on EMEM was kept at 0.1%.
Cell  viability  assay.  The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (Promega, WI, USA) was performed to evaluate the cyto-
toxicity of tested compounds against Vero cells and BHK21 cells according to the manufacturer’s protocol. 
Briefly, monolayers of Vero cells were grown in 96-well plate and were treated with different concen-
trations of each compound in triplicate together with negative control (media containing 0.1% DMSO). 
The plate was then incubated at 37 °C with 5% CO2 for 48 hours before the MTS assay was performed. 
Treated and control cells were kept for two days at 37 °C, under similar conditions and duration until 
used for antiviral activity assay. After two days post-treatment, MTS solution was added to the cells and 
incubated for 4 hours at 37 °C with 5% CO2 prior to absorbance detection at 495 nm wavelength using 
Infinite 200 Pro multiplate reader (Tecan, Männedorf, Switzerland). All experiments were conducted in 
triplicate. The half maximal cytotoxic concentration (CC50) for each compound was determined through 
this assay using Graph Pad Prism 5 (Graph Pad Software Inc., San Diego, CA, USA, 2005).
Antiviral activity assays. Primary assay for antiviral activity. A monolayer of Vero cells were grown 
in 96-well plate in EMEM containing 2% inactivated FBS. The tested compounds were added to the wells 
in triplicate together with CHIKV at an MOI =  1. The plate was then incubated at 37°C with 5% CO2 
for 48 hours. The assay was conducted in duplicate for each concentration of each compound. After two 
days, the plate was viewed under the microscope and the degree of cytopathic effect (CPE) as measure 
of virus replication inhibition was expressed as the percent yield of virus control (% virus control = CPE 
experimental group/CPE virus control × 100). The results were confirmed by performing the MTS assay 
(Promega, WI, USA) according to the manufacturer’s protocols. All experiments were repeated three 
times independently. The statistical analysis on percentage of CPE inhibition was performed by using 
the Gaussian populations (Pearson) two-tailed assay.
Anti-entry assay.  The procedure of the anti-entry assay was modified and performed according to 
Lee RCH et. al., 201334. Monolayers of Vero cells were grown in 96-well plate with EMEM supplemented 
with 10% inactivated FBS. The Vero cells were then infected with CHIKV and the plate was incubated 
for 1 hour at 4 °C. Non-adsorbed virus was then washed with 1xPBS. Tested compound was added in 
different concentrations and incubated at 37 °C with 5% CO2 for 2 hours. The plate was again washed 
with 1xPBS and treated with citrate buffer (pH = 3) to inactivate the non-internalized virus, before the 
plate was again washed with 1xPBS. The EMEM supplemented with 2% inactivated FBS was added into 
every wells and the plate was incubated for 48 hours at 37 °C with 5% CO2.
CHIKV replicon cell line based assay.  Monolayers of CHIKV replicon cells were prepared in 96-well 
white plate (Corning Inc, NY, USA) and treated with different concentrations of tested compounds. 
After 48 hours incubation at 37°C with 5% CO2 the activity the Renilla Luciferase (Rluc), expressed by 
CHIKV replicon, was detected using Renilla luciferase assay (Promega, WI, USA) performed according 
to the manufacturer’s protocols. The luminescence signal was then measured using the GloMAX 20/20 
Luminometer (Promega, WI, USA), plotted against the log transformation of the concentrations of com-
pounds and a sigmoidal curve fit with variable slope was created to obtain the half maximal inhibitory 
concentration (IC50) value for each compound by Graph Pad Prism 5 (Graph Pad Software Inc., San 
Diego, CA, USA, 2005). Data were represent as the means ± standard error of the mean (SEM) from 
triplicate assay from three independent experiments. The statistical analysis to determine the correlation 
between the concentration of silymarin and the Rluc activity was performed by using non-parametric 
correlation (Spearman) two-tailed assay.
Time-of-addition assay.  In this experiment, a monolayer of Vero cells were grown in 96-well plate 
in EMEM containing 2% inactivated FBS. The wells (in triplicate) were designated as − 2, − 1, 0, 2, 4, 6 
and 8-hour, that they are named according to the time of CHIKV (MOI = 1) infection. As for − 2 hour, 
Vero cells were treated with 100 μ g/ml of silymarin. The plate was then incubated for one hour at 37 °C 
with 5% CO2. One hour later, − 1 hour wells were also treated with 100 μ g/ml of silymarin. At the 0 hour, 
all wells except the control wells were infected with CHIKV and again incubated for one hour at 37 °C 
with 5% CO2. After 2-hour incubation and for every 2-hour after incubation at 37 °C with 5% CO2, 
100 μ g/ml silymarin were added to − 2, 4, 6 and 8 hour wells respectively. The plate was then 
incubated at 37 °C with 5% CO2 for 48 hours.
The supernatant of the treated and control wells (treated with 0.1% DMSO was used as vehicle con-
trol) were collected two days post-treatment and analyzed using qRT-PCR. The half maximal effective 
concentration (EC50) of silymarin was calculated using Graph Pad Prism 5 (Graph Pad Software Inc., San 
Diego, CA, USA, 2005). All data are from triplicate assay from three independent experiments.
Quantitative reverse transcription PCR(qRT-PCR).  A qRT-PCR assay was used to quantify the CHIKV 
RNA copy number. For this amplification of 136 base region of nsP3 encoding sequence was performed as 
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described by Chiam and colleagues35. The primers were nsP3-F(5’-GCGCGTAAGTCCAAGGGAAT-3’) 
and nsP3-R (5’-AGCATCCAGGTCTGACGGG-3’). The cDNA was first generated from the RNA 
extracted from the supernatants (QIAGEN, Germany) of the previous assays plate, using nsP3-R primer 
and Superscript III Reverse Transcriptase (Life Technologies, USA) according to the manufacturer’s pro-
tocol. The unincorporated primers were then digested with 20U of Exonuclease I (New England Biolabs, 
USA). The qRT-PCR was performed with a Step-OnePlus Real-Time PCR System (Life Technologies, 
USA) with 2 × Power SYBRGreen PCR Master Mix (Life Technologies, USA), following the manufac-
turer’s protocol, and using serially diluted standards. Cycling parameters were 95 °C for 10 min, 40 cycles 
of 95°C for 15 s and 60 °C for 1 min. The amplified product was verified by melting curve analysis. The 
statistical analysis to determine the correlation between the RNA copy number and the silymarin con-
centration was performed by using the Gaussian populations (Pearson) two-tailed assay.
Western blotting.  Vero cells at the density of 3 × 106 cells were seeded into a 75 cm2 flask in EMEM 
containing 2% FBS and penicillin-streptomycin. The next day, each flask was infected with CHIKV inoc-
ulum at an MOI = 1, placed on a rocker for 30 minutes, and then incubated at 37 °C with 5% CO2 for 
2 h. Then each flask was treated with different concentrations (100, 50, 25, 12.5, 6.25 μ g/ml) of the trial 
compound, control flasks were treated with solutions containing 0.1% DMSO. All the flasks were then 
incubated at 37 °C with 5% CO2 until the appearance of CPE in the vehicle control. Once CPE was 
observed, cells were scraped, washed with PBS and lysed using 300 μ l of 1% Triton X100 (Sigma-Aldrich, 
St. Louis, MO, USA) containing complete protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, 
USA) at 4 °C for 45 min. Cellular debris was pelleted out by centrifugation at 16,000 × g for 5 min. A 
Micro BCATM Protein Assay Kit (Thermo Scientific, Rockford, IL) was used to quantify the protein con-
centration for each sample. Lysate containing 100 μ g of protein were denatured using SDS-loading buffer 
and proteins were separated using SDS-PAGE in 12% gels. The gels were then equilibrated in Towbin 
buffer (0.025 M Tris, 0.192 M glycine 20% methanol) for 10 min and proteins were transferred to a PVDF 
membrane using the Bio-Rad wet transfer system (Bio Rad, San Francisco, CA). For detection of nsP1 
and nsP3, membranes were blocked with 1X PBS 1% Casein Blocker (Bio Rad, San Francisco, CA) for 
1 h at room temperature on a shaker. The blots were rinsed three times with 1X PBS Tween20 before 
being incubated with primary anti-CHIKV nsP1, anti-CHIKV nsP3 or anti-CHIKV E2 rabbit polyclonal 
antibodies in 1% casein solution. The blots were then washed three times with 1X PBS Tween20 for 
15 min each time. This was followed by incubation with the secondary goat anti-rabbit IgG (Abcam, 
Cambridge, UK) antibodies conjugated with horseradish peroxidase (HRP) for 1 h at room temperature 
on an orbital shaker. Membranes were washed three times with PBS containing Tween 20 for 15 minutes 
each time. For the loading control, separate blots containing the same samples were incubated with pri-
mary anti-β-actin mouse monoclonal antibody conjugated with HRP (Cell Signaling Technology, MA, 
USA) dissolved in 1% Casein for 1 hour at room temperature on shaker. The blots were then washed 
three times with 1X PBS Tween 20 for 15 minutes each time. Membranes were developed by the colori-
metric method using appropriate substrates (Thermo Scientific, Rockford, IL).
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